2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
21
Leukemia, Myelomonocytic, Chronic
12
Myeloproliferative Disorders
4
Triple Negative Breast Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Biphenotypic, Acute
2
Anemia, Refractory, with Excess of Blasts
2
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Patient Preference
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
decitabine and cedazuridine drug combination
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn